glp 1 agonist fda approved for weight loss Approves Oral Semaglutide as First GLP-1 Pill Comparing Ozempic, Wegovy and Other
Description
The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer
Disclaimer: This article is for informational purposes only and is not medical advice
AstraZeneca, Novo Nordisk A/S, Eli Lilly and Company, Sanofi and Hypera S.A
Clinicians should maintain heightened awareness for aspiration risk in perioperative settings
Origin: USA
